IL‐1 antagonists have been successfully used to treat uveitis in monogenic autoinflammatory diseases such as Blau syndrome and cryopyridine‐associated periodic syndrome or in complex polygenic autoinflammatory diseases such as Behçet's disease.16, 17. Here, IL1B is linked to Blau syndrome.